{"id":"W2808864948","doi":"10.1136/esmoopen-2018-000361","title":"Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"ESMO Open","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology; Genentech; GlaxoSmithKline; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Discontinuation; Oncology; Metastatic breast cancer; Meta-analysis; Breast cancer; Adverse effect; Neutropenia; PARP inhibitor; Population; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006861151,0.0007479239,0.01086509,0.0002060287,0.0001410872,0.00007904647,0.0003791688,0.0000925147,0.0008206913],"category_scores_gemma":[0.00006710648,0.0003220121,0.001920786,0.001122849,0.0002486686,0.0001084163,0.00006527189,0.0001115046,0.0000105661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006298673,"about_ca_system_score_gemma":0.0003979042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001215973,"about_ca_topic_score_gemma":0.0004810655,"domain_scores_codex":[0.9961606,0.0007028493,0.001632533,0.000701789,0.0005079358,0.0002942953],"domain_scores_gemma":[0.994891,0.0008855207,0.002322539,0.001070848,0.0006703654,0.000159761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0001378472,0.0007551246,0.00001573281,0.4923227,0.5001175,0.000004711516,0.0003317463,0.000001190933,9.933778e-9,0.000004994167,0.0009051742,0.005403313],"study_design_scores_gemma":[0.001611921,0.001082502,0.00001641806,0.06054107,0.8716587,0.00002005316,0.00003564479,0.000002675477,0.000005864021,0.000006758883,0.06472597,0.0002923729],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006855327,0.966957,0.00005875233,0.0004935644,0.00005482446,0.02877623,0.003591416,0.0000157993,0.00004560911],"genre_scores_gemma":[0.00006587735,0.9792897,0.0005054284,0.0004098044,0.00004025306,0.01831573,0.0004773763,0.00009027163,0.0008055471],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4317816,"threshold_uncertainty_score":0.9999232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1524902586108739,"score_gpt":0.4081192647699527,"score_spread":0.2556290061590788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}